
Unicycive Therapeutics (UNCY) Stock Forecast & Price Target
Unicycive Therapeutics (UNCY) Analyst Ratings
Bulls say
Unicycive Therapeutics Inc. is showing promising potential due to its focused clinical-stage development of innovative therapies for kidney disease, particularly with the anticipated launch of oxylanthanum carbonate (OLC) in the third quarter of 2026. The company has demonstrated effective management of its development and regulatory strategies, addressing critical issues highlighted by a previous Complete Response Letter (CRL) and now preparing for potential FDA approval. Despite adjustments to financial models and expectations concerning sales and operating expenses, the overall positive outlook is supported by the company's strategic partnerships and ongoing discussions with key payers to secure reimbursement, thereby aiding in the potential commercialization of its product candidates.
Bears say
Unicycive Therapeutics faces considerable risks that could impede its sales potential and negatively impact its valuation, particularly regarding delays in the market launch of oxylanthanum carbonate (OLC) and challenges related to reimbursement and commercial execution. Current market conditions suggest a valuation of $83 million, with projected revenues reaching nearly $625 million by 2031; however, this growth outlook is tempered by concerns over regulatory challenges and execution risks. Additionally, anticipated share dilution from milestone events may artificially suppress the stock price, contributing to an overall negative sentiment regarding its financial outlook.
This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction
Start investing in Unicycive Therapeutics (UNCY)
Order type
Buy in
Order amount
Est. shares
0 shares